Related references
Note: Only part of the references are listed.CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia (vol 66, pg 515, 2020)
Guozhu Xie et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment
Steven Van Schandevyl et al.
ACTA CLINICA BELGICA (2020)
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Maria-Luisa Schubert et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Steering CAR T cells to distinguish friend from foe
Hillary G. Caruso et al.
ONCOIMMUNOLOGY (2019)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
William G Wierda et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
Shivani Srivastava et al.
CANCER CELL (2019)
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
Claire Perrinjaquet et al.
CURRENT OPINION IN NEUROLOGY (2019)
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Mohit Sachdeva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
Utkarsh H. Acharya et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies
Benjamin Heyman et al.
CANCERS (2019)
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice
Muhua Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
Prasad S. Adusumilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Yushu Joy Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
SO-009Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
E Van Cutsem et al.
ANNALS OF ONCOLOGY (2019)
Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy
Cassie K. Chou et al.
BONE MARROW TRANSPLANTATION (2019)
ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
Mark A Rosenthal et al.
NEURO-ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Kamal Chamoun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
Prasad S. Adusumilli et al.
CANCER RESEARCH (2019)
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
Maria-Luisa Schubert et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
Paola Bocca et al.
ONCOIMMUNOLOGY (2018)
Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics
Marta Overchuk et al.
BIOMATERIALS (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
A guide to manufacturing CAR T cell therapies
Philipp Vormittag et al.
CURRENT OPINION IN BIOTECHNOLOGY (2018)
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Ping-Pin Zheng et al.
DRUG DISCOVERY TODAY (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Nanobody Based Dual Specific CARs
Stijn De Munter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Erhao Zhang et al.
MOLECULAR CANCER (2018)
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
Katarzyna C. Pituch et al.
MOLECULAR THERAPY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-\-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
Ayguen Sahin et al.
PLOS ONE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
The development of CAR design for tumor CAR-T cell therapy
Dandan Xu et al.
Oncotarget (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumors evading CARs-the chase is on
Sarwish Rafiq et al.
NATURE MEDICINE (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Making CAR T Cells a Solid Option for Solid Tumors
Andrea Schmidts et al.
FRONTIERS IN IMMUNOLOGY (2018)
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Loretta J. Nastoupil et al.
BLOOD (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells
Hinrich Abken
HUMAN GENE THERAPY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Robert Sackstein et al.
LABORATORY INVESTIGATION (2017)
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang et al.
MOLECULAR THERAPY (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
Iulia Diaconu et al.
MOLECULAR THERAPY (2017)
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
Aaron E. Foster et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Sanja Stevanovic et al.
SCIENCE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
Melinda Mata et al.
CANCER DISCOVERY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
A versatile system for rapid multiplex genome-edited CAR T cell generation
Jiangtao Ren et al.
ONCOTARGET (2017)
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Markus Chmielewski et al.
CELL REPORTS (2017)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu et al.
CELL REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas et al.
FRONTIERS IN IMMUNOLOGY (2017)
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Yongping Zhang et al.
FRONTIERS OF MEDICINE (2017)
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
Thivyan Thayaparan et al.
ONCOIMMUNOLOGY (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
Irene Scarfo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita et al.
SCIENTIFIC REPORTS (2017)
CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target
Astrid Holzinger et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia
Y. Liu et al.
DRUGS OF TODAY (2017)
Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
Jochen Buechner et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy
Gideon Gross et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII plus glioblastoma
Donald M. O'Rourke et al.
CANCER RESEARCH (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans et al.
PROSTATE (2016)
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Kaichao Feng et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response
Maria Themelil et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Medical management of side effects related to CAR T cell therapy in hematologic malignancies
Manjusha Namuduri et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape
Cameron J. Turtle et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
Reona Sakemura et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Adrienne H. Long et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapies
Kentaro Minagawa et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Next frontiers in CAR T-cell therapy
Christine E. Brown et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
CAR models: next-generation CAR modifications for enhanced T-cell function
Daniel Abate-Daga et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
Imran Siddiqui et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jeremy S. Abramson et al.
BLOOD (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
H. Singh et al.
CANCER GENE THERAPY (2015)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials
Saumya Ravianayake et al.
CYTOTHERAPY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Engineering CAR-T cells: Design concepts
Shivani Srivastava et al.
TRENDS IN IMMUNOLOGY (2015)
Revisiting the Mechanisms of CNS Immune Privilege
Antoine Louyeau et al.
TRENDS IN IMMUNOLOGY (2015)
Overcoming Antigen Escape with CAR T-cell Therapy
Hollie J. Jackson et al.
CANCER DISCOVERY (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Enxiu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru et al.
ONCOIMMUNOLOGY (2015)
Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
Anthony K Park et al.
Journal for ImmunoTherapy of Cancer (2015)
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Sonia Guedan et al.
BLOOD (2014)
Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells
Victor D. Fedorov et al.
CANCER JOURNAL (2014)
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Ko Kudo et al.
CANCER RESEARCH (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma
Bryan D. Choi et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Ann M. Leen et al.
MOLECULAR THERAPY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor
Partow Kebriaei et al.
BLOOD (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors
Paul Spear et al.
ONCOIMMUNOLOGY (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
Grazyna Lipowska-Bhalla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Receptor Tyrosine Kinases and TLR/IL1 Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid et al.
CANCER CELL (2011)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses
Weiyi Peng et al.
CLINICAL CANCER RESEARCH (2010)
The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
John S. Bridgeman et al.
JOURNAL OF IMMUNOLOGY (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2008)
Adoptive transfer of effector CD8(+) T cells derived from central memory cells establishes persistent T cell memory in primates
Carolina Berger et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
Scott T. James et al.
JOURNAL OF IMMUNOLOGY (2008)
Cancer and Immune Response: Old and New Evidence for Future Challenges
Luis de la Cruz-Merino et al.
ONCOLOGIST (2008)
CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma
Naoko Kanagawa et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
MA Pulè et al.
MOLECULAR THERAPY (2005)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Persistence of multiple tumor-specific T-Cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
JH Zhou et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration
E Lavergne et al.
JOURNAL OF IMMUNOLOGY (2004)
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
KS Kahlon et al.
CANCER RESEARCH (2004)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Human T lymphocyte genetic modification with naked DNA
MC Jensen et al.
MOLECULAR THERAPY (2000)
Share Paper
